RNA ▲ +0.2% - Atrium Therapeutics, Inc.
$RNA - Atrium Therapeutics Doses First Patient in Corventis™, the First Interventional Clinical Trial for People Living with PRKAG2 Syndrome
27-OCT-2026 06:33 AM ET
Share this post
More filings for $RNA
RNA ▲ +2.3% - Atrium Therapeutics, Inc.Oct 20, 2026RNA ▲ +2.8% - Atrium Therapeutics, Inc.Sep 21, 2026RNA ▲ +3.7% - Atrium Therapeutics, Inc.Sep 2, 2026$RNA SEC Filing Update (27-JUL-2026) | ThinkSabio - Stocks SimplifiedJul 27, 2026
View full $RNA filing history →💬 Comments
Loading comments…
Leave a comment